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HIGH DOSE CHEMOTHERAPY FOLLOWED BY STEM CELL RESCUE IN AD-
OLESCENTS WITH EWING’S SARCOMA
Tatman, D.J., Rumelhart, S.L., Radhi, M.A. University of Iowa, Iowa
City, IA.
Ewing Sarcoma (ES) is the second most common bone tumor in
children and young adults. About two thirds of patients with local-
ized disease will have long term survival. However, patients with
metastatic disease at diagnosis and patients with progressive or re-
current disease have dismal chance of survival. High dose chemo-
therapy (HDC) followed by autologous stem cell rescue (ASCR)
has not been shown to be unequivocally helpful in a randomized
clinical trial. However, several smaller studies have shown clear
benefit for HDC in a subset of patients. In this case series we report
three consecutive patients with recurrent ES. Each subject or guard-
ian signed an IRB-approved consent to participate in this study.
Two patients had localized recurrence of their disease while one pa-
tient had bonemarrow involvement at recurrence. Patients received
carboplatin, etoposide (VP), cyclophosphamide (CPM) and topote-
can for salvage chemotherapy. Once a complete remission (CR) was
achieved, each patient went directly to transplant using a condition-
ing regimen of either CPM/VP/Thiotepa (TT) (UPN1) or Busul-
fan/Melphalan/TT (UPN2 and UPN3). The patient with positive
BM involvement was ES negative by PCRprior to transplant. These
regimens were well tolerated and none of the patients experienced
serious adverse events in the peri or post transplant periods. Median
graft size was 5.46 and range 3.0–10.0  106 CD341/Kg All pa-
tients had myeloid engraftment on a timely basis (range 11–13
days) and had a range in length of stay of 37–44 days. Median sur-
vival was 19 months, with range of 10–24 months. All patients are
alive and disease free to date. Following transplant, Lansky/Karnof-
sky scores were 80–90 at 2 months and all scores were $ 90 at 6
months. Conclusions that can be drawn from this small series in-
clude: 1) HDC followed by ASCR can be well tolerated; 2) durable
remission can be achieved following this therapy; and 3) trans-
planted patients can be expected to have good quality of life post
transplant.
Patient data
LengthPatient
ID
Age at
ASCRPrimary
site of
disease rSite of
ecurrence
Time to
relapse
(mo) ATime from
dx to
SCR (mo)Initial
therapy
pof CR
ost ASCR
(mo)UPN1 15 spine spine 47 54 Adria/VP/Ifos 24UPN2 14 nasal fossa spine 32 37 Vin/Adria/CPM 19UPN3 19 chest chest, BM 41 47 Vin/Adria/CPM 10Adria: Adriamycin; Vin: Vincristine; Ifos: Ifosfamide.
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OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION FOR 26
CHILDREN WITH MYELOID LEUKEMIA IN SINGLE CENTER
Chen, J., Jiang, H., Dong, L., Luo, C., Wang, Y. Shanghai Children’s
Medical Center, China.
Background & Objective: Children with acute myeloid leuke-
mia (AML) have poor prognosis. Treated with chemotherapy alone,
they can hardly survive if the disease is refractory or relapse. Al-
though the onset of chronic myeloid leukemia (CML) is relatively
slow and treatment with Gleevec will further prolong the survival
time, it still can not be cured by the targeting treatment. Allogeneic
hematopoietic stem cell transplantation will be the only way to cure
these diseases. The purpose of this paper was to clarify the role of
hematopoietic stem cell transplantation treating patients with mye-
loid leukemia. Methods: A total of 26 consecutive patients with
AML and CML in a single institution between May 2001 and Sep-
tember 2006 were included. Among them, 8 were chronic myeloid
leukemia (CP 5 5, AP 5 2, BP 5 1) and 18 were AML (CR1 5 9,
CR2 5 7, Non CR 5 2).5 out of 9 AML got CR1 after at least 2
courses of chemotherapy. The average age was 9.4 years old(range
2 years17 years)and the average body weight 32.8 kg (range 11.5kg79 kg), Patients underwent allogeneic peripheral blood stem
cell transplantation (allo-PBSCT) from HLA-identical siblings (n
5 2), mismatched family donors (n5 4), andmatched unrelated do-
nors(n 5 20). All patients received myeloablative regimens with
1620 mg/kg busulfan and 200 mg/kg cyclophosphomide. For
aGVHD prophylaxis patients with HLA-identical sibling donors
received cyclosporine (CSA) and methetraxate, while patients with
matched unrelated donors received CSA, methotrexate and 15
mg/kg rabbit ATG(Fresenius). After Jan.2004 mycophenolate mo-
fetil were used to enhance GVHD prophylaxis for CML patients.
Results: After a average follow-up of 20.5 months(955 months),
2 (7.6%)patients graft rejected, 7 (27%) patients developed grade
34 aGVHD (all with CML), 5 patients having extensive cGVHD.
At present, 9 patients have died of relapse (4/26) and TRM (GVHD
4/26 and infection 1/26) while 17 (65%) patients are still alive with
disease-free survival.Conclusion:Our evidences is convincing that
allogeneic stem cell transplantation is conducive to improve the sur-
vival rate for children with acute myeloid leukemia and the GVHD
associated with unrelated donor transplants can be controlled after
take active prevention measures. As to whether the GVHD hap-
pened was more severe in children with CML than that of children
with AML, It still remain to have more patients and more institu-
tions collaboration to confirm such a conclusion.
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SUCCESSFUL COMBINED UNRELATED UMBILICAL CORD BLOOD HAP-
LOIDENTICAL TRANSPLANT IN NON MALIGNANT DISEASE
Kleiner, G.I.1, Barredo, J.1, Shariatmadar, S.1, Khan, A.2, Pahwa, R.2,
Rodriguez, M.1, Willumsen, S.1, Podda, A.1, Fernandes, C.1,
Alvarez, O.1, Kritzer-Cheren, M.1, Tzakis, A.1, Rubinstein, P.3,
Kurtzberg, J.4. 1 University of Miami Miller School of Medicine, Miami,
FL; 2 Diabetes Research Institue University of Miami, Miami, FL; 3 Na-
tional Cord Blood Program, New York, NY; 4 Duke Medical Center, Dur-
ham, NC.
Over the past decade, UCB transplantation has become a viable
alternative donor stem cell source for HSCT in patients with cata-
strophic diseases treatable with transplantation therapy. UCB cell
dose is the best predictor of outcomes after UCB transplantation.
In patients receiving lower cell doses, there are significant delays
and sometimes failures in myeloid and platelet engraftment. Com-
bined unit transplantation is currently under study to overcome
some of these barriers.We took an alternative approach to facilitate
early myeloid engraftment after myeloablative preparative condi-
tioning for a teenager with HLH and previous Aspergillus pneumo-
nia. Our hypothesis was that as the immunocompetent UCB cells
engrafted, the subject would reject the immunologically incompe-
tent haplo-identical HSCT graft and the patient would convert to
full UCB donor. We predicted faster myeloid engraftment in this
setting. A 15 year old boy with common variable immune deficiency
and HLH refractory to medical therapy underwent myeloablative
conditioning with standard TBI/CY/ATGAM and received a com-
posite graft consisting of a 1) 5/6 UCB which delivered 2.5  107
TNC/KG and 2) 2  106/KG CD34 selected PSSC collected
from the father. The subject engrafted on day 9. Initial chimerism
was predominantly (.80%) the haplo donor. This was followed
by an increase in UCB chimerism (.90% on D1 17). The subject
was fully reconstituted with UCB by D1 32. The subject later de-
veloped Grade IV GVHD of liver and intestine at the time of full
UCB engraftment that was treated with MSCs and liver transplan-
tation. This combined UCB/Haplo approach has the advantage of
faster myeloid engraftment than double UCB transplant in subjects
at high risk of infectious complications and or graft failure.242
UNRELATED CORD BLOOD TRANSPLANTATION (UCBT) IN PEDIATRIC
PATIENTS: A SINGLE CENTER EXPERIENCE IN CHILE
Barriga, F.J., Wietstruck, M.A., Zun˜iga, P. Catholic University of Chile,
Santiago, Chile.
Umbilical cord blood (CB) from unrelated donors is being used
increasingly in pediatric stem cell transplantation and it represents
90 Poster Session Ian easily available source of stemcells for patients everywhere. The
increasing worldwide repository of CB units is improving the chan-
ces of finding a matched unit for more patients. We present our ex-
perience with UCBT as a single source of stem cells for unrelated
transplantation in these patients.
CBSearchMethods:Matched unrelated CB searches were done
for 67 pediatric pts (0–16 yrs) with malignant (MD, n 5 44) and
nonmalignant (NMD, n 5 23) disease from 1995 to 2007 in the
NY Blood Center and Netcord. The probability of finding a 5/6
CB unit with. 3.0  10 7/kg (optimal match) was calculated com-
paring the period 1995–2001 vs 2002–07.Transplant Patients and
Methods: 32 pts. (MD5 19, NMD5 13) receivedUCBT between
1996 and 2007. 12 pts with MD were standard risk (SR) for trans-
plantation (ALL CR1–2, ANLL CR1, CML CP, MDS RAEB/
RAEBt).1 pt received a 3/6, 18 a 4/6, 13 pts a 5/6 graft. Median
cell dose was 4.3  107/kg (2.6–16.3). 3 pts received a double graft.
Conditioning regimens were adapted to diagnosis. NMD received
BuCyATG. 17 MD pts and 1 NMD pt received TBI. GvHD pro-
phylaxis was CsA plus prednisone (n 5 26), mtx (n 5 2) or MMF
(n 5 4). Engraftment and EFS analysis was done for the entire
group of transplanted pts and the MDSR plus NMD subset (n 5
25). HLA match (5/6 vs others), cell dose (\4.0 vs .4.0 10 7/kg)
and year of UCBT (96–01 vs 01–07) were compared for engraft-
ment and survival in this subset. Results: An optimal matched CB
unit was found for 6/41 pts (14%) in the 1995–2001 period vs 17/
26 (65%, p . 0.001) in the 2001–2007 period. 19 transplanted pts
(61%) engrafted. TRM was 25%, MD relapse 22%. EFS was
31% with median f/u of 21 months. Subset analysis of MDSR
plus NMD pts showed engraftment of 70% and 3 yr EFS of 36%.
In this group the only prognostic factor for survival wasHLAmatch
(5/6 vs 3/6 and 4/6:Hazard Ratio 14, p\0.001).Conclusion:CB is
a good alternative for unrelated stem cell transplantation in chil-
dren. HLA matching appears to be the most important prognostic
factor given a cell dose . 3.0  10 7/kg. Increasing availability of
optimal matched CB units worldwide will make this approach fea-
sible for more patients.243
AUTOLOGOUS STEM CELL TRANSPLANTATION IN CHILDREN WITH RE-
FRACTORY OR RELAPSED HODGKIN DISEASE IN COLOMBIA
Linares, A., Abello, V., Rosales, C., Pedraza, E., Esguerra, H.J.,
Rosales, M.L. Clınica de Marly, Bogota, Colombia.
Here we report a retrospective analysis performed to evaluate the
results of autologous hematopoietic stem cell transplantation in pe-
diatric patients withHodgkinDisease (HD) in a single center in Bo-
gota, Colombia.
Nineteen patients with relapsed or refractory HD underwent au-
tologous stem cell transplantation between 1998 and 2006. 8 fe-
male/11 male, with mean age of 10.9 years (7–14). At diagnosis
patients were staged: I and IIA 10, IIB 1, IIIA 1, IIIB 4 and stage
IV 6. The response to first line therapy was: 8 patients had failure
to induction, and 6 early relapse (before 12 months). At transplan-
tation: 10 patients were in 2nd complete remission, 2 in 3th com-
plete remission and 7 were in partial remission. The conditioning
regimenwas BEAM in 14 patients and other protocols with carmus-
tine, etoposide and cyclophosphamide or melphalan in 5 patients.
With a mean 26 months of follow-up, (8–66), the 5 year OS was
73.3% and EFS of 51.9%. 8/19 patients (42%) relapsed between 3
and 48 months after transplantation, the main cause of death was
progressive disease. One patient died before day1100 with a severe
fungal infection.
This study group is too small to establish prognostic factors for
relapse after transplantation, although is important for countries
with limited resources to have data about local results. The OS
and EFS in this group are similar to results in developed countries.
Near 50% of patients with refractory or relapsed HD can be suc-
cessfully treated with high dose chemotherapy and autologous
stem cell rescue. It’s important to have a longer follow up on these
patients so we can perform analysis on prognostic factors for relapse
and survival.SOLID TUMORS
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TREATMENT OF EPSTEIN BARR VIRUS POSITIVE NASOPHARYNGEAL
CARCINOMA WITH ADOPTIVELY TRANSFERRED CYTOTOXIC T LYM-
PHOCYTES
Louis, C.U., Straathof, K., Gerken, C., Cooper-Havlik, D., Torrano, V.,
Lopez, T., Bollard, C.M., Gresik, M.V., Weiss, H., Gee, A.,
Brenner, M.K., Rooney, C.M., Heslop, H.E., Gottschalk, S. Baylor Col-
lege of Medicine, The Methodist Hospital, Texas Children’s Hospital,
Houston, TX.
Background: The strong association of nasopharyngeal carci-
noma (NPC) with Epstein-Barr virus (EBV) makes adoptive immu-
notherapy with EBV-specific cytotoxic T cells (EBV-CTL) an
attractive therapeutic option. We have evaluated the safety and ef-
ficacy of EBV-specific CTL (EBV-CTL) in two Phase I clinical tri-
als. In the first trial, EBV-CTL were given alone and in the second
trial, we aimed to enhance in vivo expansion of EBV-CTL by lym-
phodepleting patients prior to CTL infusion. For lymphodepletion
we used CD45 monoclonal antibodies (MAbs) that unlike chemo-
therapy or radiation do not result in nonspecific destruction of
the resident immune system. Study Design:The primary objective
of these Phase I clinical trials was to determine the safety of escalat-
ing doses of EBV-CTL with or without lymphodepletion in EBV-
positive NPC patients. The secondary objective was to determine
the expansion, persistence and anti-tumor effects of infused EBV-
CTL. Results: Thirty two patients with advanced-stage NPC re-
ceived autologous EBV-CTL. Patients received a median of 2
(range 1–6) doses of CTL at 2  107–2 108 cells/m2 per infusion.
CTL administration was well tolerated except for transient swelling
at known disease sites in 4 patients. Prior to CTL infusion, 8 pa-
tients were in remission, 22 had active disease, and 2 had abnormal
imaging studies of unknown significance. Seven of 8 patients in re-
mission prior to CTL infusion remain in remission 6–64 months
post CTL. For the remaining 24 patients, the best overall response
rate was 50% with 6 complete responses (CR/CRu), 2 partial re-
sponses, and 4 with stable disease during a median follow-up of 9
months (95%CI 2–16months). Of the 6 with a CR: 4 have been sus-
tained for 2–4 years, and 2 relapsed more than 2 years post CTL.
Ten patients with active disease received CD45 MAbs prior to
EBV-CTL and 8 were evaluable for immune reconstitution analy-
sis. Infusion of CD45 MAbs resulted in transient lymphopenia (re-
solved within 7 days), increased serum IL-15 levels in 6 patients, and
significant expansion of EBV-CTL within 8 weeks post-infusion in
3 patients. Conclusion: Treatment of EBV-positive NPC with
EBV-CTL appears safe and can be associated with significant
anti-tumor activity. Lymphodepletion with CD45 MAbs prior to
CTL infusion is also safe and results in expansion of adoptively
transferred CTL in a subset of patients. These encouraging results
warrant further exploration of EBV-targeted immunotherapies for
NPC.245
REGRESSION OF EXPERIMENTAL OSTEOSARCOMA AND EWING’S SAR-
COMA FOLLOWING TRANSFER OF HER2-REDIRECTED T CELLS
Ahmed, N.1, Salsman, V.S.1, Louis, C.L.1, Dishop, M.1, Weiss, H.L.1,
Kleinerman, E.S.2, Rooney, C.M.1, Heslop, H.E.1, Gottschalk, S.1,3.
1 Baylor College of Medicine, Houston, TX; 2 University of Texas, Hous-
ton, TX; 3 Baylor College of Medicine, Houston, TX.
Background: New therapies are needed for osteosarcoma (OS)
and Ewing’s sarcoma (EWS) since the prognosis for patients with
metastatic and/or recurrent disease has not improved over the last
two decades despite aggressive multimodal therapies. For immuno-
therapies,HER2 is an attractive target since it is expressed in 40%
of OS and up to 25% of EWS.While the use of HER2 monoclonal
antibodies has been limited by low levels of HER2 expression on
sarcoma cells, we show here that T cells expressing HER2-specific
chimeric antigen receptors (CARs) have potent anti-sarcoma activ-
ity in animal models. Methods: Mitogen-activated T cells were
transduced with a retroviral vector encoding a HER2-specific
CAR with a CD28.z-signaling endodomain (HER2-T cells). We
